SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NTEG- Bloodless Glucose Monitor
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brander who wrote (36)9/30/1997 3:23:00 PM
From: William T. Katz   of 176
 
Brad,

I have been lurking on this group since I'm very interested in the diabetes market. It sounds like you have some information from preclinical trials and are able to cite accuracy. Is your information from optimal condition studies or do they reflect actual use in a home, on the road, etc? A number of the points raised earlier on the TCPI system point to errors that can occur during using under non-ideal conditions [and as we know, patients will find ways to stress instruments not apparent in the lab].

Have you managed diabetic patients in your practice? What kind of accuracy do you think is required in order to maintain "optimal" control? Obviously, diabetic patients do better the more closely their glucose is controlled and there is probably no clear lines between optimal and non-optimal. But in your opinion, what will the diabetic clinics think is sufficient and will that "sufficient" regimen be changed if someone like Integ comes out with a more precise monitoring system?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News